Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.

McConoughey SJ, Basso M, Niatsetskaya ZV, Sleiman SF, Smirnova NA, Langley BC, Mahishi L, Cooper AJ, Antonyak MA, Cerione RA, Li B, Starkov A, Chaturvedi RK, Beal MF, Coppola G, Geschwind DH, Ryu H, Xia L, Iismaa SE, Pallos J, Pasternack R, Hils M, Fan J, Raymond LA, Marsh JL, Thompson LM, Ratan RR.

EMBO Mol Med. 2010 Sep;2(9):349-70. doi: 10.1002/emmm.201000084.

2.

Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.

Borrell-Pagès M, Canals JM, Cordelières FP, Parker JA, Pineda JR, Grange G, Bryson EA, Guillermier M, Hirsch E, Hantraye P, Cheetham ME, Néri C, Alberch J, Brouillet E, Saudou F, Humbert S.

J Clin Invest. 2006 May;116(5):1410-24. Epub 2006 Apr 6.

3.

Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain.

Kim SY, Marekov L, Bubber P, Browne SE, Stavrovskaya I, Lee J, Steinert PM, Blass JP, Beal MF, Gibson GE, Cooper AJ.

Neurochem Res. 2005 Oct;30(10):1245-55.

PMID:
16341586
4.

Transglutaminase cross-links in intranuclear inclusions in Huntington disease.

Zainelli GM, Ross CA, Troncoso JC, Muma NA.

J Neuropathol Exp Neurol. 2003 Jan;62(1):14-24.

PMID:
12528814
5.

Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.

Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, Mitchell D, Steinman L.

Nat Med. 2002 Feb;8(2):143-9. Erratum in: Nat Med 2002 Mar;8(3):303.

PMID:
11821898

Supplemental Content

Loading ...
Support Center